Status:
UNKNOWN
Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Autoimmune Encephalitis
Anti NMDA Receptor Encephalitis
Eligibility:
All Genders
Brief Summary
Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antivi...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in the CSF
- After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF
- Without age limit
- Exclusion Criteria- No respect of inclusion criteria
Exclusion
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04339127
Start Date
April 1 2020
End Date
October 1 2020
Last Update
April 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospice Civils de Lyon
Bron, France, 69500,